Detecting 2009 Pandemic Influenza A (H1N1) Virus Infection: Availability of Diagnostic Testing Led to Rapid Pandemic Response
Detecting 2009 Pandemic Influenza A (H1N1) Virus Infection: Availability of Diagnostic Testing Led to Rapid Pandemic Response
复制标题
DOI：
10.1093/cid/ciq020
复制
发表时间：
2011-01-01
影响因子：
11.8
通讯作者：
Shaw, M. W.
中科院分区：
文献类型：
--
作者：
Jernigan, D. B.;Lindstrom, S. L.;Shaw, M. W.
用于检测具有大流行潜力的新出现流感病毒株的诊断测试对于指导全球流感预防和控制活动至关重要。2008年，疾病控制和预防中心获得了美国食品和药物管理局对一种高度敏感的流感聚合酶链反应（PCR）测定方法的批准。设备被部署到美国和全球的公共卫生实验室。在首次确认2009年H1N1大流行性流感的两周内，疾病控制和预防中心开发并开始分发一种新的批准的H1N1大流行性流感PCR检测方法，该方法使用先前部署的设备平台，使提交的标本数量增加了80倍。临床医生在护理点广泛使用快速抗原检测；然而，检测灵敏度较低（40%-69%）。许多临床实验室开发了自己的H1N1大流行性流感PCR检测方法，以满足临床医生的需求。未来的规划工作应确定改善可靠检测的可用性的方法，以管理患者护理，以及最佳利用分子检测来检测和控制新出现的流感病毒株的方法。
Diagnostic tests for detecting emerging influenza virus strains with pandemic potential are critical for directing global influenza prevention and control activities. In 2008, the Centers for Disease Control and Prevention received US Food and Drug Administration approval for a highly sensitive influenza polymerase chain reaction (PCR) assay. Devices were deployed to public health laboratories in the United States and globally. Within 2 weeks of the first recognition of 2009 pandemic influenza H1N1, the Centers for Disease Control and Prevention developed and began distributing a new approved pandemic influenza H1N1 PCR assay, which used the previously deployed device platform to meet a > 8-fold increase in specimen submissions. Rapid antigen tests were widely used by clinicians at the point of care; however, test sensitivity was low (40%-69%). Many clinical laboratories developed their own pandemic influenza H1N1 PCR assays to meet clinician demand. Future planning efforts should identify ways to improve availability of reliable testing to manage patient care and approaches for optimal use of molecular testing for detecting and controlling emerging influenza virus strains.